HC Wainwright Issues Negative Estimate for KYMR Earnings

Posted by Brenda Bartman on Aug 12th, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Kymera Therapeutics in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($1.04) per share for the quarter, down from their prior forecast of ($0.69). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($3.78) per share. HC Wainwright also issued estimates for Kymera Therapeutics’ Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($4.22) EPS, FY2028 earnings at ($4.32) EPS, FY2029 earnings at ($3.70) EPS and FY2030 earnings at $0.22 EPS.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. During the same quarter last year, the firm earned ($0.95) earnings per share. The business’s revenue for the quarter was up 465.2% on a year-over-year basis.

A number of other analysts also recently issued reports on the company. Guggenheim raised their target price on Kymera Therapeutics from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a research report on Monday, June 8th. Bank of America upped their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. Finally, Mizuho lifted their target price on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. Twenty research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $125.65.

View Our Latest Research Report on Kymera Therapeutics

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $109.62 on Monday. The stock’s fifty day moving average is $102.68 and its two-hundred day moving average is $89.49. The firm has a market capitalization of $9.11 billion, a P/E ratio of -33.83 and a beta of 1.95. Kymera Therapeutics has a fifty-two week low of $37.57 and a fifty-two week high of $130.05.

Insider Buying and Selling

In other news, insider Noah Goodman sold 3,389 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total transaction of $387,328.81. Following the completion of the transaction, the insider directly owned 47,179 shares in the company, valued at approximately $5,392,087.91. This represents a 6.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Nello Mainolfi sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total value of $5,950,000.00. Following the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $79,321,592. The trade was a 6.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,604,813 shares of company stock valued at $387,557,004. 15.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Kymera Therapeutics during the second quarter valued at about $1,386,000. E Fund Management Co. Ltd. acquired a new position in shares of Kymera Therapeutics in the 2nd quarter worth approximately $597,000. Eagle Health Investments LP acquired a new position in shares of Kymera Therapeutics in the 2nd quarter worth approximately $19,052,000. Merck & Co. Inc. acquired a new position in shares of Kymera Therapeutics in the 2nd quarter worth approximately $88,544,161,000. Finally, BlackRock Inc. purchased a new position in shares of Kymera Therapeutics during the 2nd quarter worth approximately $635,067,000.

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.